The project titled “Structure-Based Design, Synthesis, and Biological Activity Evaluation of ROR1 Kinase Inhibitor Benzimidazole–Phthalazinone/Pyridazinone Hybrids for the Treatment of Triple-Negative Breast Cancer,” led by Assoc. Prof. İsmail ÇELİK from the ERU Department of Pharmaceutical Sciences of the Faculty of Pharmacy, has been awarded funding by TÜBİTAK under the TÜBİTAK 1001 – Scientific and Technological Research Projects Funding Programme. The project team includes Res. Asst. Burak Kırılmaz and Res. Asst. Merve Yıldırım, from the Department of Pharmaceutical Sciences of the Faculty of Pharmacy, and Prof. Dr. Tamer Yağcı and Res. Asst. Arzu Aysan, from the Department of Molecular Biology and Genetics at Gebze Technical University, as researchers.

Congratulations to our researchers and the project team, and we wish them continued success.